Quick answer
A study from Zhejiang University, published in Molecular Psychiatry (online December 2025), found that gut bacteria from people in a bipolar depressive phase can directly cause depression-like behaviors when transplanted into mice. The mice showed reduced activity, less interest in rewards, and weakened brain connections — changes that improved with lithium but not with the common antidepressant fluoxetine.
Key takeaways:
- Mice receiving bipolar patients' gut bacteria displayed core depression behaviors
- These mice responded to lithium (a mood stabilizer) but not fluoxetine (an antidepressant)
- The gut bacteria specifically weakened the VTA-mPFC dopamine pathway in the brain
- Reduced synaptic plasticity and dendritic spine density in the prefrontal cortex
- Six inflammation-associated bacterial genera were enriched in bipolar patients' microbiota
The experiment: transplanting bipolar microbiomes
Researchers collected fecal samples from patients in the depressive phase of bipolar disorder and from healthy controls. They eliminated the recipient mice's own gut bacteria with antibiotics, then transplanted the human microbial communities by oral gavage.
The results were striking. Mice receiving bipolar patients' microbiota showed:
Behavioral changes:
- Reduced movement and exploration — less total distance, fewer center crossings, less time in the center (open-field test)
- Increased despair-like behavior (longer immobility in the forced swim test)
- Reduced pleasure from sweet water (sucrose preference test) — a sign of anhedonia
- Notably, the tail suspension test showed no significant increase in immobility — the behavioral signature was specific, not a blanket shutdown
Drug response pattern: When treated with lithium, a standard mood stabilizer for bipolar disorder, the mice's behavior improved. But when given fluoxetine (Prozac), a common antidepressant, there was no improvement.
This drug sensitivity profile mirrors what clinicians see in human bipolar depression, where antidepressants alone often don't work and can sometimes make things worse — and it's the strongest sign the model captured something specifically bipolar, not generic rodent depression.
What the bacteria did to the brain
The research team used multiple techniques to trace how gut bacteria influenced brain function.
Synaptic changes in the prefrontal cortex
RNA sequencing of the medial prefrontal cortex (mPFC) — a brain region critical for mood regulation — revealed:
- 202 genes upregulated, 64 downregulated
- Downregulated genes linked to dendritic spine plasticity
- Upregulated genes involved in immune responses
- "Postsynaptic translation" was the most suppressed biological process — the cellular machinery that builds the proteins long-term synaptic plasticity depends on. qPCR confirmed reduced expression of the relevant ribosomal and elongation-factor genes (Rpl, Rps, Eef, Uba families)
Physical analysis confirmed these molecular changes. Pyramidal neurons in layers II/III and V of the mPFC showed significantly reduced total dendritic spine density. Individually, none of the three spine subtypes reached statistical significance, but the reduction was most pronounced in mushroom-type spines — the mature, stable connections associated with long-term memory and stable circuits.
Dopamine pathway disruption
Using rabies virus-based neural tracing, the researchers mapped monosynaptic inputs to mPFC glutamatergic neurons from across the brain, analyzing the four major neuromodulatory systems: acetylcholine (basal forebrain), dopamine (VTA and substantia nigra), serotonin (dorsal raphe), and norepinephrine (locus coeruleus). Most pathways remained intact, but one showed clear damage: the VTA-mPFC dopaminergic pathway.
The ventral tegmental area (VTA) is a major source of dopamine to the prefrontal cortex. This pathway is essential for motivation, reward processing, and mood regulation.
What changed:
- Only the dopaminergic input showed a significant reduction in viral labeling — the cholinergic, serotonergic, and noradrenergic inputs were unchanged
- Fewer VTA dopamine neurons formed synaptic connections with mPFC glutamatergic neurons (confirmed with rabies tracing plus tyrosine hydroxylase staining)
- A decreasing (non-significant) trend in the total number of VTA dopamine neurons projecting to the mPFC
- Reduced dopamine release in the mPFC during stimulation, measured in real time with a genetically encoded dopamine sensor and fiber photometry
The researchers also found circuit specificity beyond the VTA-mPFC main pathway: in neurons belonging to the mPFC-to-basolateral-amygdala circuit, inputs from the VTA were absent in the bipolar-microbiota mice. The microbiota's effect was not diffuse inflammation across the brain — it selectively targeted dopamine circuits that regulate reward and mood.
This dopamine deficiency likely explains the anhedonia and motivational deficits seen in both the mice and human bipolar depression.
The bacterial signature
16S rRNA sequencing revealed that mice successfully acquired microbiome characteristics from their human donors. The bipolar-associated microbiota showed:
Enriched bacteria:
- Six inflammation-associated genera (named genera include Klebsiella and Alistipes)
Depleted bacteria:
- Several beneficial genera, including Citrobacter and Enterobacter
The mice's microbial profiles showed high overlap with human bipolar patients — 259 shared bacterial species — validating the model's relevance.
This study provides some of the strongest experimental evidence that gut bacteria can directly influence mood-related brain circuits.
Key implications:
Causal, not just correlational: Most human microbiome studies can only show associations. This transplant experiment shows causality — bipolar microbiota caused bipolar-like brain and behavioral changes.
Specific neural mechanism: The gut-brain connection isn't vague. These bacteria specifically targeted the dopamine pathway between VTA and prefrontal cortex — a circuit already implicated in bipolar disorder through other research.
Drug response validity: The fact that mice responded to lithium but not fluoxetine suggests the microbiota-induced changes reproduce something fundamental about bipolar depression's neurobiology, not just generic depression.
Therapeutic potential: If gut bacteria contribute to bipolar symptoms, then modifying the microbiome could become a treatment avenue — through probiotics, prebiotics, or sometimes even fecal transplants.
How this fits the wider evidence
This is not the first transplant study to connect bipolar microbiota to brain changes. An earlier joint clinical-and-animal study from related research found that bipolar patients carried elevated TRANK1 (a bipolar genetic-risk gene) signaling linked to gut-microbiota involvement, and that mice harboring bipolar-derived microbiota showed depressive-like phenotypes with raised inflammatory cytokines and TRANK1 expression in the hippocampus and prefrontal cortex. The new study extends that work from inflammatory markers to a specific, measured neural circuit — and from correlation to a model whose drug-response pattern validates it.
On the human side, microbiome dysbiosis is now a well-replicated observation across psychiatric disorders — bipolar disorder, major depression, and schizophrenia all show altered gut communities, though the specific genera differ between studies. What the transplant experiments add is direction: in the gut-to-brain direction, the microbiota is sufficient to produce brain and behavioral changes, not just a byproduct of being ill. For the general mechanism and its evidence across disorders, see the gut-brain axis and anxiety and how gut health affects mental clarity.
Limitations and next steps
While convincing, this research has important caveats:
Mouse models are imperfect: Mice don't develop true bipolar disorder with manic and depressive episodes. The study captured depression-like features, not the full human condition — the lithium-over-fluoxetine response is a partial, not complete, validation.
Correlation vs. causation in humans: The study doesn't prove that gut bacteria cause bipolar disorder in people. The microbiome changes could result from the illness, medications (especially lithium and antipsychotics, which themselves alter the microbiome), diet, or lifestyle factors.
Treatment implications are distant: Fecal transplants for psychiatric conditions remain experimental. Much more research is needed before clinical applications, and no microbiome-based therapy for bipolar disorder exists today.
Effect details still emerging: The preprint-to-print process means some mechanistic specifics — exact spine-subtype statistics, the dose and duration of lithium treatment — should be read from the full text and its supplementary data rather than summaries.
Practical takeaways
For people with bipolar disorder or their families, this research suggests:
- Gut health may matter for mood stability — supporting a healthy microbiome through diet (fiber, fermented foods) could complement standard treatments, though no gut intervention replaces medication
- Don't abandon proven treatments — medication and therapy remain essential; microbiome interventions are not ready for clinical use
- The future may hold new options — as research progresses, microbiome-based treatments or VTA-mPFC-targeted neuromodulation could become part of the bipolar management toolkit
Gut-brain research moves fast — for related coverage of how gut bacteria influence cognition, see gut bacteria and memory decline.
Study details
Journal: Molecular Psychiatry (published online December 2025; print issue May 2026) Institution: Zhejiang University, China Methods: Fecal microbiota transplantation, 16S rRNA sequencing, RNA sequencing, rabies virus neural tracing, fiber photometry with a genetically encoded dopamine sensor Key researchers: Shaohua Hu, Jianbo Lai, Wei Gong (Zhejiang University)
FAQ
Q: Does this mean bipolar disorder is caused by gut bacteria? A: No. The study shows transplanted bacteria from bipolar patients can produce depression-like brain changes in mice — causal evidence in one direction. Human bipolar disorder involves genetics, environment, and physiology together, and whether the microbiome differences cause the illness or result from it (or both) is exactly what the next round of research must answer.
Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. Bipolar disorder requires professional diagnosis and treatment; never change or stop medications without consulting a healthcare provider.